New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
10:01 EDTALGT, APC, ED, YUM, TIF, SBLK, NS, NTI, NM, MTRN, KIRK, IPHI, HA, HEES, COG, BOBE, BIIB, AXLL, TEVAOn The Fly: Analyst Upgrade Summary
Allegiant Travel (ALGT) upgraded to Outperform from Market Perform at Raymond James... Axiall (AXLL) upgraded to Buy from Neutral at Goldman... Biogen (BIIB) upgraded to Outperform from Market Perform at BMO Capital... Bob Evans (BOBE) upgraded to Buy from Hold at Miller Tabak... Cabot Oil & Gas (COG) upgraded to Buy from Neutral at UBS... H&E Equipment (HEES) upgraded to Buy from Neutral at UBS... Hawaiian Holdings (HA) upgraded to Buy from Hold at Deutsche Bank... Inphi (IPHI) upgraded to Buy from Hold at Jefferies... Kirkland's (KIRK) upgraded to Buy from Hold at KeyBanc... Materion (MTRN) upgraded to Buy from Hold at KeyBanc... Navios Maritime (NM) upgraded to Buy from Hold at Stifel... Northern Tier (NTI) upgraded to Overweight from Equal Weight at Barclays... NuStar Energy (NS) upgraded to Overweight from Neutral at JPMorgan... Star Bulk Carriers (SBLK) upgraded to Buy from Hold at Stifel... Tiffany (TIF) upgraded to Buy from Neutral at Citigroup... Yum! Brands (YUM) upgraded to Outperform from Neutral at RW Baird... Consolidated Edison (ED) upgraded to Buy from Hold at Argus... Anadarko (APC) upgraded to Buy from Hold at Argus... Teva (TEVA) upgraded to Outperform from Market Perform at Leerink.
News For ALGT;AXLL;BIIB;BOBE;COG;HEES;HA;IPHI;KIRK;MTRN;NM;NTI;NS;SBLK;TIF;YUM;ED;APC;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 8, 2014
09:36 EDTYUMYum! Brands expects China business to 'fully recover'
Subscribe for More Information
09:20 EDTYUMOn The Fly: Pre-market Movers
Subscribe for More Information
08:05 EDTTEVATeva initiates NDA submission to FDA for CEP-33237
Teva Pharmaceutical announced the initiation of a rolling New Drug Application submission to the U.S. Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Teva’s proprietary technology providing potential abuse-deterrent properties CEP-33237 as allowed for fast track designated products. Teva expects to complete the NDA submission by the end of 2014. Teva also announced positive results from a nasal Human Abuse Liability study which supports the NDA. The nasal HAL study found that in nondependent, recreational opioid users, abuse potential for crushed intranasal CEP-33237 was significantly lower than intranasal immediate-release hydrocodone. Teva has now completed positive HAL studies in the two most common routes of hydrocodone abuse, oral and intranasal. CEP-33237 demonstrated a safety profile in the Phase III study that is consistent with the known safety profile of hydrocodone and other opioid analgesic therapies. Adverse events reported in 5% or more of hydrocodone-treated patients during either the titration or double-blind treatment periods included nausea, constipation, vomiting, headache, somnolence and dizziness.
07:29 EDTYUMYum! comp weakness in China has bottomed, says UBS
UBS believes Yum! Brands' recovery in China is under way, but that visibility remains limited following yesterday's Q3 results. The firm still has many questions about company strategy, but believes China comp weakness has bottomed. UBS maintains its Buy rating and $85 price target on Yum! Brands shares.
07:20 EDTYUMYum! Brands outlook still positive, says Stifel
After Yum! reported weaker than expected results ex-items, Stifel continues to expect the company to eventually carry out a significant restructuring that could include a partial listing of its China unit in Hong Kong and/or a $15 per share debt recapitalization. The firm continues to believe that Yum! China is one of the best retail businesses in the world. It cut its price target on Yum! to $105 from $110 but keeps a Buy rating on the shares.
06:47 EDTTEVALawmakers may push for new regulations on generic drug makers, NY Times says
After the prices of some generic drugs soared more than 1,000% over the last year, two influential members of Congress are probing the sector and threatening to look to impose new regulations on it, according to The New York Times. Generic drug makers include Teva (TEVA), Mylan (MYL), Actavis (ACT), and Lannett (LCI).Reference Link
06:22 EDTSBLKStar Bulk Carriers coverage assumed with a Buy at Maxim
Target $17.
October 7, 2014
17:18 EDTYUMYum! Brands reverses direction in after-hours trading, up 1.1%
Subscribe for More Information
16:39 EDTALGTAllegiant Travel reports September passenger traffic up 13.2% to 468,240
Subscribe for More Information
16:35 EDTIPHIInphi initiated with an Outperform at Northland
Subscribe for More Information
16:31 EDTYUMYum! Brands reports Q3 China SSS down 14%
Subscribe for More Information
16:24 EDTYUMYum! Brands down 1% following Q3 results
16:23 EDTYUMYum! Brands expects to develop at least 700 new restaurants in China this year
Subscribe for More Information
16:22 EDTYUMYum! Brands lowers FY14 EPS growth ex-items to 6%-10%
Subscribe for More Information
16:19 EDTYUMYum! Brands provides China update
Subscribe for More Information
16:15 EDTYUMYum! Brands reports Q3 EPS ex-items 87c, consensus 89c
Reports Q3 revenue $3.35B, consensus $3.48B. Worldwide system sales grew 1%. Worldwide restaurant margin decreased 2.7 percentage points to 14.9%, and worldwide operating profit decreased 12%.
15:16 EDTYUMNotable companies reporting after market close
Subscribe for More Information
14:27 EDTYUMYum! Brands October weekly 70 straddle priced for 4.6% move into Q3
Subscribe for More Information
13:03 EDTYUMYum! Brands technical notes ahead of results
The shares have markedly under-performed in the prior three months, trading down over 14%. A great deal of the share price loss came at the front of the interval during the tainted-meat scandal in China. After the initial drop, shares have been basing in a range of $70 at the low and $73 at the high. The base at $70 may be particularly important. If the news is worse than already low expectations, that support at the $70 area could be lost. Next support below would be at $68.20 and then at $66.16. An extreme price reaction could see the 52-week low at $64.08 tested as well or perhaps broken. Equally, an upside surprise could see the top of the range tested at $73. Given low expectations, a bit of stronger news could push the stock through that resistance level. Next upside would be at $73.84, $75.44, and then at $76.33 on an increasing band of positive surprises.
07:24 EDTBIIBAlliance for Regenerative Medicine
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use